Clinical Trials
39 trialsNimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis
Tianjin Medical University Cancer Institute and Hospital
Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma
Sun Yat-sen University
Study of Post-Op Adjuvant Concurrent Chemo-RT With or Without Nimotuzumab for Head & Neck Cancer
National Cancer Centre, Singapore
DIPG
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors
Tianjin Medical University Second Hospital
GCR-05
Xi'an Jiaotong University
TRUMP
Guangdong Association of Clinical Trials
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
Sun Yat-sen University
A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma
China Three Gorges University, Yichang, China
Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery
Eye & ENT Hospital of Fudan University
Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University
Carpp-1
The First Affiliated Hospital of Soochow University
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer
Hebei Medical University
Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma
ChineseAMS
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
ChineseAMS
By Comparing TPF Induction Chemotherapy Combined With Nimotuzumab Concurrent Radiotherapy and Cisplatin Concurrent Radio-chemotherapy for Locally Advanced NPC
Guiyang Medical University
Nimotuzumab in Combination With Radio-chemotherapy for the Treatment of Brainstem Tumor in Children
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Nimotuzumab for Recurrent Nasopharyngeal Carcinoma
Fujian Cancer Hospital
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
Zhujiang Hospital
Immunotherapy of Advanced Cancer Using a Combination Nimotuzumab and NK Cells
Hangzhou Cancer Hospital
NIEGA
Peking University
Nimotuzumab Plus S1 Versus Placebo Plus S1 as Maintenance Treatment in Patients With Unresectable Pancreatic Cancer
Chinese PLA General Hospital
Phase II Clinical Trial of Concurrent Chemoradiotherapy Combined Nimotuzumab for Stage IIB-IVA Cervical Cancer
Air Force Military Medical University, China
NSCLC
Tianjin Medical University Cancer Institute and Hospital
Nimotuzumab in Combination With Chemoradiation for Nasopharyngeal Cancer
Biotech Pharmaceutical Co., Ltd.
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell Carcinoma
Biotech Pharmaceutical Co., Ltd.
Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Cervical Cancer
Biotech Pharmaceutical Co., Ltd.
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
Biotech Pharmaceutical Co., Ltd.
Pharmacokinetics Study of Nimotuzumab in Patients With Solid Tumors
Biotech Pharmaceutical Co., Ltd.
Nimotuzumab Plus Docetaxel and Capecitabine Versus Docetaxel and Capecitabine in the Treatment of Breast Cancer Patients
ChineseAMS
Afatinib Plus Nimotuzumb for NSCLC
Samsung Medical Center
Study of Nimotuzumab to Treat Esophageal Squamous Cell Carcinoma.
Peking University
Combination of Nimotuzumab,Capecitabine and Radiotherapy for Inoperable or Recurrent Gastric Cancer
ChineseAMS
Nimotuzumab in Combination With Chemoradiation in Patients With Locally Advanced Rectal Cancer
Zhejiang Cancer Hospital
Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer
The Second People's Hospital of Sichuan
Nimotuzumab
Fudan University
Nimotuzumab Plus Paclitaxel and Cisplatin as 1st Line Treatment for Esophageal Squamous Cell Cancer
Peking University
Study of Nimotuzumab to Treat Colorectal Cancer
Peking University